Royal Bank Of Canada Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Key Points

• The Royal Bank of Canada has increased its price target for Regeneron Pharmaceuticals from $688.00 to $695.00, suggesting a potential upside of 22.61% from the last closing price.
• Analysts have varied ratings on the stock, with sixteen buy ratings, two strong buy ratings, and one sell rating, in addition to an average price target of $839.26.
• Regeneron Pharmaceuticals' shares traded up 1.4% to $566.85 with a notable market capitalization of $61.20 billion.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target lifted by Royal Bank Of Canada from $688.00 to $695.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's target price points to a potential upside of 23.45% from the stock's current price.

Several other research firms have also recently issued reports on REGN. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research note on Friday, August 1st. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $841.30.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $3.20 during trading on Monday, reaching $563.00. 1,024,297 shares of the company's stock traded hands, compared to its average volume of 969,491. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a current ratio of 4.60, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $60.78 billion, a P/E ratio of 14.19, a PEG ratio of 1.89 and a beta of 0.33. The firm's 50-day moving average is $536.80 and its 200 day moving average is $599.75.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the company posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Citizens Financial Group Inc. RI grew its holdings in Regeneron Pharmaceuticals by 237.4% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 2,659 shares of the biopharmaceutical company's stock worth $1,396,000 after acquiring an additional 1,871 shares during the last quarter. Westwood Holdings Group Inc. grew its holdings in Regeneron Pharmaceuticals by 17.0% in the 2nd quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company's stock worth $7,117,000 after acquiring an additional 1,974 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Regeneron Pharmaceuticals by 5.9% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,469 shares of the biopharmaceutical company's stock worth $13,371,000 after acquiring an additional 1,409 shares during the last quarter. Grandfield & Dodd LLC grew its holdings in Regeneron Pharmaceuticals by 6.0% in the 2nd quarter. Grandfield & Dodd LLC now owns 35,205 shares of the biopharmaceutical company's stock worth $18,483,000 after acquiring an additional 1,998 shares during the last quarter. Finally, First Western Trust Bank grew its holdings in Regeneron Pharmaceuticals by 6.4% in the 2nd quarter. First Western Trust Bank now owns 545 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 33 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.